Drug Trial Radar · NCT05671510
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
630
Planned (sponsor's estimate)
Start
Jun 28, 2023
Primary completion
Aug 31, 2027
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- OncoC4, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Jan 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.
Conditions
- Non Small Cell Lung Cancer
Interventions
GotistobartDrug
Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
DocetaxelDrug
Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: 36 months
Locations
152 sites in 12 countries. Site status is shown where the registry gives one.
XCancer/Dothan Hematology & Oncology - 1114
Dothan, Alabama
Genesis Cancer and Blood Institute - 1123
Russellville, Arkansas
The Oncology Institute (TOI) Clinical Research - 1109
Cerritos, California
Emad Ibrahim MD Inc. - 1147
Redlands, California
UC Davis Comprehensive Cancer Center - 1103
Sacramento, California
Bass Medical Group - 1155
Walnut Creek, California
Nuvance Health - 1118
Norwalk, Connecticut
D&H Cancer Research Center LLC - 1153
Margate, Florida
Ocala Oncology Center PL - 1102
Ocala, Florida
AdventHealth Cancer Institute - 1105
Orlando, Florida
Orlando Health - 1130
Orlando, Florida
Florida Cancer Specialists -South - 1126
Sarasota, Florida
Florida Cancer Specialists -North - 1125
The Villages, Florida
Florida Cancer Specialists -East - 1124
West Palm Beach, Florida
Orchard Healthcare Research, Inc. - 1116
Skokie, Illinois
Springfield Clinic - The Cancer Center - 1110
Springfield, Illinois
Fort Wayne Medical Oncology - 1133
Fort Wayne, Indiana
Deaconess Chancellor Center for Oncology - 1131
Newburgh, Indiana
Cotton O'Neil Clinical Research Center - 1151
Topeka, Kansas
University of Kentucky - Markey Cancer Center - 1112
Lexington, Kentucky
Norton Cancer Institute - 1108
Louisville, Kentucky
Jefferson City Medical Group - 1145
Jefferson City, Missouri
MidAmerica Cancer Care - 1163
Kansas City, Missouri
Astera Cancer Care - 1128
East Brunswick, New Jersey
Duke University Medical Center - 1158
Durham, North Carolina
Miami Valley Hospital - 1115
Centerville, Ohio
University of Cincinnati Cancer Center - 1107
Cincinnati, Ohio
The Ohio State University James Cancer Center - 1104
Columbus, Ohio
Tri County Hematology & Oncology Associates, Inc - 1156
Massillon, Ohio
Oklahoma Cancer Specialists and Research Institute - 1154
Tulsa, Oklahoma
Oncology Associates of Oregon - 1138
Eugene, Oregon
St. Luke's University Health Network - 1179
Bethlehem, Pennsylvania
Donald Guthrie Foundation - 1135
Sayre, Pennsylvania
Cancer Care Associates of York, Inc. - 1113
York, Pennsylvania
University of Tennessee Medical Center - 1146
Knoxville, Tennessee
Sarah Cannon Research Institute - Tennessee Oncology at Nashville - 1119
Nashville, Tennessee
Texas Oncology - Baylor Charles A. Sammons Cancer Center (USOR) - 1140
Dallas, Texas
Texas Oncology - Denison - 1139
Denison, Texas
Oncology Consultants, P.A. - 1120
Houston, Texas
Oncology and Hematology of South Texas - 1165
Laredo, Texas
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.